What the Indictment of Former AstraZeneca Executive Means for Multinational Pharmaceutical Companies in China

In November 2025, Chinese authorities formally charged former AstraZeneca executive Leon Wang, a Chinese national, with medical insurance fraud, illegal trade, and unlawful collection of personal information. Wang had been detained for investigation approximately one year earlier. The allegations are reportedly linked to earlier investigations into misconduct by former AstraZeneca employees involved in local sales and market access activities.

The indictment represents one of the most prominent law enforcement actions involving a multinational pharmaceutical company in China in recent years. It carries important implications for foreign biopharmaceutical companies operating in China, particularly in areas such as compliance management, local leadership structures, and operational strategies.

Rather than being interpreted as a crackdown specifically targeting foreign companies, the indictment should be understood in the broader context of the anti-corruption campaign focused in China’s healthcare sector, which began in 2023 and continued through 2024 and 2025. The charges against Wang closely align with the priorities of this campaign, which targets bribery, improper sales practices, and the misuse of medical insurance funds across healthcare institutions, pharmaceutical companies, and drug distribution networks. The campaign intensified further in 2025 amid an evolving regulatory environment for pharmaceutical companies in China.

Regulatory Trend Concerning Pharmaceutical Companies in 2025

China’s regulatory environment for pharmaceutical companies has tightened considerably in recent years. Two regulatory developments in 2025 are particularly relevant.

The first development is the Compliance Guidelines for Pharmaceutical Companies on Prevention of Commercial Bribery Risks (医药企业防范商业贿赂风险合规指引), which were issued by the State Administration for Market Regulation (国家市场监督管理总局) in January 2025.^[1] The guidelines identified nine key risk areas:

• Academic promotion activities;
• Hospitality to healthcare professionals during commercial events;
• Consulting services involving healthcare professionals;
• Outsourced commercial activities;
• Discount and rebates;
• Donations and sponsorships;
• Provision of free medical equipment;
• Clinical trials and research activities; and
• Retail sales.

The guidelines encourage pharmaceutical companies to establish robust compliance management systems, conduct internal risk assessments, and develop internal reporting mechanisms for suspected misconduct.

More broadly, the guidelines reflect a shift from reactive enforcement to preventive compliance governance, and emphasize corporate responsibility to detect and mitigate bribery risks before enforcement action occurs. Its emphasis on third-party risks is particularly relevant for multinational pharmaceutical companies, as their reliance on contract distributors and third-party sales channels has historically created compliance vulnerabilities.

The second development are the June 2025 amendments to the Anti-Unfair Competition Law (反不正当竞争法).^[2] The amendments strengthen the law’s anti-bribery provisions and include several notable changes:

• Explicit penalties for both bribe givers and bribe takers;
• Expanded liability to include legal representatives and principal responsible individuals for bribery; and
• Higher administrative fines for commercial bribery violations.

These amendments signal a transition toward dual corporate and individual accountability, raising potential exposure of senior corporate executives to personal liability.

Taken together, these regulatory developments point to a clear policy trajectory toward stronger compliance oversight, individual accountability, and stricter control of pharmaceutical sales practices.

Key Implications for Multinational Pharmaceutical Companies

The indictment of Wang carries several important implications for multinational pharmaceutical companies operating in China.

First, Wang’s case highlights the growing risk of personal liability for corporate executives. While past enforcement actions against pharmaceutical companies in China often focused on corporate fines or administrative penalties, recent regulatory trend and enforcement patterns indicate a growing willingness by authorities to pursue individuals deemed responsible for compliance failures.

The Wang case reinforces this trend. Foreign companies may face greater expectations to demonstrate that senior leadership actively supervises compliance programs and maintain effective oversight of commercial activities. In this context, multinational companies may also need to reassess their China-based leadership structures, including reporting lines, compliance responsibilities, and decision-making authority within local operations.

Second, the AstraZeneca case illustrates Chinese regulators’ heightened scrutiny of aggressive sales practices. The allegations in the Wang case—medical insurance fraud, illegal trading, and unlawful data collection—likely stem from aggressive sales tactics driven by pressure to meet high sales target. For years, pharmaceutical companies, domestic and multinational, relied heavily on aggressive sales practices to drive market growth in China. However, the Wang case underscores the authorities’ growing concerns regarding sales-driven commercialization practices, which have become a central focus of regulatory enforcement in the healthcare sector.

This case suggests that the previous model of prioritizing sales performance over compliance oversight is gradually being replaced by an approach that emphasizes sustainable, compliance-aligned commercialization.

Multinational pharmaceutical companies operating in China may therefore need to carefully review their sales practices, incentive structure, and contract distribution networks to ensure practices comply with relevant Chinese regulatory requirements.

Third, multinational pharmaceutical companies are likely to face intensifying regulatory scrutiny in China. Although China’s anti-corruption campaign applies across the entire healthcare sector, multinational pharmaceutical companies may draw disproportionate scrutiny due to their market visibility and complex organizational structures. High-profile enforcement actions involving foreign firms can serve signaling purposes, demonstrating regulatory resolve and reinforcing policy priorities.

As a result, multinational pharmaceutical companies may face more frequent inspections, audits, and investigations by Chinese authorities. Companies with large sales teams, extensive hospital engagement networks, or reliance on third-party commercial partners may face particularly elevated regulatory risks.

Fourth, Chinese regulators are increasing their focus on data privacy and data governance. Another notable aspect of the Wang case is the allegation of unlawful collection of personal information, highlighting the growing intersection between healthcare regulation and data governance policy in China.

China’s broader legal framework, including the Personal Information Protection Law, Data Security Law, and Cybersecurity Law, imposes strict requirements on the collection, storage, and cross-border transfer of personal data. Multinational pharmaceutical companies are particularly exposed to these regulations because many of their activities—clinical trials, real-world research studies, and patient support programs—involve sensitive personal data. Multinational pharmaceutical companies conducting such activities in China must carefully navigate these regulatory requirements. The Wang case shows that alleged misconduct involving personal data may trigger enforcement under both healthcare and data security regulatory frameworks.

Opportunities and Risks

Notwithstanding the regulatory challenges highlighted by the AstraZeneca case, China remains one of the most important pharmaceutical markets in the world. As the world’s second-largest pharmaceutical market, China continues to present substantial opportunities for multinational pharmaceutical companies. The country’s rapidly aging population, expanding healthcare coverage, rising public and private healthcare spending, and increasingly innovative domestic biotechnology sector all support long-term market growth.

At the same time, the indictment of Leon Wang highlights the evolving regulatory risks faced by multinational pharmaceutical companies operating in China. The changing regulatory landscape does not necessarily diminish China’s importance as a pharmaceutical market. However, it underscores the increasingly central role of compliance in achieving commercial success for multinational pharmaceutical companies in China. To navigate China’s evolving, complex regulatory system, multinational companies need professional advice to help them make major business decisions.

Contact us to see how Pamir can help you manage your risks so you can maximize your China opportunities.

^[1] //https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/jjjzs/art/2025/art_0cee28b1eba84820addc024b351b7bac.html//

^[2] //https://www.zhonglun.com/research/articles/54733.html//